Compare IDEXX Laboratories, Inc. (IDXX) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs IAC/Interactivecorp — how do they compare? IDEXX Laboratories, Inc. trades at $517.55 (market cap $40.43B), while IAC/Interactivecorp trades at $41.07 (market cap $3.05B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.3× IAC/Interactivecorp's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and IAC/Interactivecorp for 79 Days on average.
| IDXX | PPLI | |
|---|---|---|
Market Cap | $40.43B | $3.05B |
Volume | 692,164 | 931,019 |
Sector | Health | Media |
52-Week High | $766.68 | $47.62 |
52-Week Low | $504.70 | $31.52 |
Typical Hold Time | 46 Days | 79 Days |
Enterprise Value | $41.32B | $3.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
PPLI trades at $40.94, up 0.86% with bullish technical signals and strong analyst support (71% buy ratings). The stock shows mixed fundamentals with a low P/E of 6.92 and P/B of 0.6, but recent earnings volatility includes two misses and one beat. Recent MGM takeover speculation has driven significant price movement, with shares surging 11.3% following acquisition discussions.
Investment outlook balances attractive valuation metrics against operational challenges. The company faces revenue decline from $5.2B (2022) to $2.4B (2025) and negative net income in 2025, though 2026 projections show recovery. Key risks include media industry headwinds and execution uncertainty, while MGM deal potential offers upside catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
